RxDoctor Payments Data

Joseph Choi, MD

Orthopaedic Surgery · Westfield, NJNPI 1396265682

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (43.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Smith+Nephew at 46.8% of the total. Reporting peaked in 2023 at $7,892 and has fallen 93.7% since, to $500 in 2025.

$11,391in general payments, 2019–2025

Across 63 payments — averaging $180.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$5K
  • Stryker$4K
  • Arthrex$1K
  • Seapearl East, Inc$192
  • Nevro Corp.$122
  • Johnson & Johnson$100
  • plus $136 from 3 others
$14,755in research payments, 2019–2025

Across 7 payments — averaging $2107.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lima USA, Inc.$15K

What the payments were for

  • Travel & lodging$3,78033%
  • Food & beverage$2,61223%
  • Education$5,00044%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,391 in reported general payments places this provider in the 70th percentile of 587 orthopaedic surgery providers in New Jersey.

See all orthopaedic surgery providers in New Jersey →

Medicare billing

Part B allowed, 2024
$127,471
Medicare patients
313
Services billed
1,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam92$371
Methylprednisolone30$187
Celecoxib28$102
Tramadol Hcl28$65
Gabapentin31$59
Oxycodone Hcl24$57
Cyclobenzaprine Hcl15$43

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Westfield

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →